FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Leerink Partnrs cut their FY2028 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $9.70 per share for the year, down from their previous estimate of $9.90. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.59) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2029 earnings at $16.85 EPS.

A number of other equities analysts also recently commented on the stock. Needham & Company LLC boosted their target price on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Bank of America upped their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $154.80.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $126.96 on Thursday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a fifty day moving average price of $99.64 and a 200 day moving average price of $94.22. The company has a market cap of $6.15 billion, a P/E ratio of -19.44 and a beta of 1.05. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AXSM. Raiffeisen Bank International AG acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $51,000. Assetmark Inc. acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $52,000. R Squared Ltd acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $64,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $76,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $86,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.